Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2020-03-20 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
独立董事关于聘请公司2020年度审计机构的事前认可意见
Audit Report / Information Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinion on the appointment of the company's 2020 annual audit firm. It references regulatory guidelines and the process of appointing the audit firm for the 2020 fiscal year. The document is short (571 characters) and does not contain actual financial statements or audit results, but rather an opinion related to the audit firm appointment. This fits the category of Audit Report / Information (AR), which includes standalone audit-related reports and opinions, excluding full annual reports. It is not an announcement of a report publication, nor a full annual report, nor a certification letter. Therefore, the best classification is AR with high confidence. FY 2020
2020-03-20 Chinese
2019年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2019 by 云南沃森生物技术股份有限公司. It extensively discusses the company's internal control systems, evaluation of their effectiveness, organizational structure, risk management, compliance with laws and regulations, and operational controls across various departments and subsidiaries. The content is detailed and comprehensive, covering internal control policies, procedures, and their implementation. This type of report aligns with the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal control evaluations, excluding full annual reports. The document is not an annual report (10-K), earnings release, or other categories. It is a detailed internal control evaluation report, fitting the AR category with high confidence. FY 2019
2020-03-20 Chinese
2019年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2019年度监事会工作报告" which translates to "2019 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight of financial and operational matters, internal controls, and compliance with laws and regulations during the 2019 fiscal year. It includes references to audit reports and internal control evaluations but does not itself contain full financial statements or detailed financial data. The document is a report from the supervisory board on their work and oversight, not a full annual report or audit report. It is a management-related report focusing on governance and supervisory activities. Therefore, the best fitting category is "Management Reports (MDA)" which covers management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports.
2020-03-20 Chinese
2019年度独立董事述职报告（万宗举）
Management Reports Classification · 95% confidence The document is titled as the "2019年度独立董事述职报告" which translates to "2019 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance, opinions, committee work, investigations, and other activities during the 2019 fiscal year. The content focuses on the director's role, opinions on board matters, and compliance with laws and regulations. It is not a full annual report (10-K), audit report, or earnings release. It is a management-related report specifically from an independent director about their work and opinions, which fits best under Management Reports (MDA). The document length is 4115 characters, which is sufficient for a substantive report rather than a brief announcement. There is no indication that this is a proxy statement, voting results, or a regulatory filing. Therefore, the classification is Management Reports (MDA).
2020-03-20 Chinese
2019年度独立董事述职报告（纳超洪）
Board/Management Information Classification · 95% confidence The document is titled as the "2019年度独立董事述职报告" which translates to "2019 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance, opinions on board meetings, committee work, investigations, investor protection, training, and other work during the year 2019. The content focuses on governance, board activities, and compliance with laws and regulations. It does not contain financial statements or audit results but rather a narrative on the independent director's role and activities. This type of document is best classified under Board/Management Information (MANG) as it relates to board member duties and governance activities rather than a full annual report, audit report, or other financial filings.
2020-03-20 Chinese
2019年度独立董事述职报告（黄伟民）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for the year 2019" from a company. It details the independent director's attendance at board meetings, opinions on various board resolutions, participation in committees, investigations, and efforts to protect investor rights. The content focuses on governance, compliance with laws and regulations, and the director's duties and opinions on company matters during the year. It does not contain financial statements or quarterly/annual financial results, nor is it a transcript, announcement, or presentation. This type of document is a report by a board member on their activities and opinions, which fits best under Board/Management Information (MANG). The document length is about 5598 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2020-03-20 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.